Evidence map›Paper›PMID 33084939›Full record

ArticleJournal of neurology2021

Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.

Chiara Zecca, Giulio Disanto, Rosaria Sacco, Sharon MacLachlan, Jens Kuhle, Sreeram V Ramagopalan, Claudio Gobbi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions.Current research in pharmacology and drug discovery · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chiara ZeccaNeurocenter of Southern Switzerland, Ospedale Regionale di Lugano Civico e Italiano, Via Tesserete 46, 6903, Lugano, Switzerland. chiara.zecca@eoc.ch.ORCID http://orcid.org/0000-0002-9990-3431
Giulio DisantoNeurocenter of Southern Switzerland, Ospedale Regionale di Lugano Civico e Italiano, Via Tesserete 46, 6903, Lugano, Switzerland.ORCID http://orcid.org/0000-0002-8512-6096
Rosaria SaccoNeurocenter of Southern Switzerland, Ospedale Regionale di Lugano Civico e Italiano, Via Tesserete 46, 6903, Lugano, Switzerland.ORCID http://orcid.org/0000-0002-6623-4649
Sharon MacLachlanEvidera, The Ark, 201 Talgarth Rd, London, W6 8BJ, UK.
Jens KuhleDepartments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6963-8892
Sreeram V RamagopalanBristol-Myers Squibb, Sanderson Rd, Denham, Uxbridge, UB8 1DH, UK.ORCID http://orcid.org/0000-0002-4766-5160
Claudio GobbiNeurocenter of Southern Switzerland, Ospedale Regionale di Lugano Civico e Italiano, Via Tesserete 46, 6903, Lugano, Switzerland.ORCID http://orcid.org/0000-0002-7554-0664

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on cancer prevalence and incidence in multiple sclerosis (MS) patients are controversial. This study is aimed at estimating cancer risk in MS patients.

methodsNested case-control study using data collected between 01/01/1987 and 28/02/2016 from the United Kingdom Clinical Practice Research Datalink. Cancer diagnoses after first MS code (index date) was counted in 10,204 MS patients and 39,448 controls matched by sex, age, general practitioner, and registration year. Cancer rates were compared using multivariable Cox regression models. Ethics approval was not required.

resultsCancer was reported in 433 (4.41%) MS patients and 2014 (5.31%) controls after index date. Cancer risk was associated with gender (HR for female = 0.88, 95% CI = 0.81-0.96, p = 0.004), age at index date (HR = 1.06, 95% CI = 1.06-1.07, p < 0.001), and index year (HR = 1.01, 95% CI = 1.00-1.02, p = 0.016), but not with MS status (HR = 0.95, 95% CI = 0.86-1.05, p = 0.323). A significant interaction between MS status and index year was found (HR = 1.02, 95% CI = 1.00-1.04, p = 0.022). Cancer risk was positively associated with index year among MS patients (HR = 1.03, 95% CI = 1.01-1.05; p = 0.010), but not controls (HR = 1.01, 95% CI = 0.99-1.02; p = 0.144). MS patients compared to controls had no increased risk for any specific cancer type.

conclusionsOverall cancer risk was similar in multiple sclerosis patients and matched controls. The frequency of cancer diagnoses has increased over time among MS patients but not in controls.

Indexed as

Multiple SclerosisNeoplasmsCase-Control StudiesFemaleHumansRiskUnited KingdomCancerCNSDemyelinating autoimmune diseasesMultiple sclerosisNeoplasmsRisk

Identifiers

PMID33084939
PMCPMC7914231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.